Skip to main content
. 2009 Mar 12;3:38–42. doi: 10.2174/1874306400903010038

Fig. (4).

Fig. (4)

Increase from baseline in the Peak Expiratory Flow (PEF) in subjects treated with the new beclomethasone/formoterol combination in extra-fine HFA formulation, in comparison with the traditional budesonide/formoterol combination. In both groups, PEF progressively increased, without any significant difference between two groups [13].